胸部立体定向体部放疗的危及器官考量:肺实质的安全剂量是什么?
该研究由美国医学物理学家协会立体定向体部放疗生物学效应工作组开展,分析了截至2016年夏季发表的97项肺SBRT研究。结果显示放射性肺毒性风险与肿瘤大小和位置相关,间质性肺病患者似乎尤其易发生严重RILT,未发现明确的耐受剂量-体积阈值,但多数研究报告在3至5次分次照射下,全肺平均肺剂量≤8 Gy且全肺V20<10%至15%时,症状性RILT发生率<10%至15%。
要点
- 放射性肺毒性风险与肿瘤大小和位置相关。
- 间质性肺病患者似乎尤其易发生严重放射性肺毒性。
- 多数研究报告全肺平均肺剂量≤8 Gy(3至5次)且V20<10%至15%时症状性RILT<10%至15%。
核心结论
- 为使该并发症得到更严格的分析,未来研究应标准化报告,包括标准化终点和体积定义,并提供所有患者(伴或不伴RILT)的剂量-体积信息。
- 未发现明确的阈值「耐受剂量-体积」水平。
- 多数研究报告在3至5次分次照射下,全肺平均肺剂量≤8 Gy且全肺V20<10%至15%时,症状性RILT发生率<10%至15%,治疗安全。
研究设计与样本
- 该研究由美国医学物理学家协会立体定向体部放疗生物学效应工作组开展。
- 分析了截至2016年夏季发表的、提供RILT详细信息的肺SBRT研究数据。
- 最终纳入97项研究。
主要发现
- 各研究对风险器官和并发症终点的定义以及提供的剂量-体积信息存在差异。
- 放射性肺毒性(包括放射性肺炎和肺纤维化)风险据报道与肿瘤大小和位置相关。
- 间质性肺病患者似乎尤其易发生严重RILT。
- 多种剂量学参数据报道与RILT相关。
- 未发现明确的阈值「耐受剂量-体积」水平。
关键数值与推荐
- 多数研究报告在3至5次分次照射下,全肺平均肺剂量≤8 Gy且全肺V20<10%至15%时,症状性RILT发生率<10%至15%。
局限性
- 各研究对风险器官和并发症终点的定义以及提供的剂量-体积信息存在差异。
- 未发现明确的阈值「耐受剂量-体积」水平。
- 未来研究应标准化报告,包括标准化终点和体积定义,并提供所有患者(伴或不伴RILT)的剂量-体积信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic body radiation therapy (SBRT) has become the standard of care for inoperable early-stage non-small cell lung cancer and is often used for recurrent lung cancer and pulmonary metastases. Radiation-induced lung toxicity (RILT), including radiation pneumonitis and pulmonary fibrosis, is a major concern for which it is important to understand dosimetric and clinical predictors. METHODS AND MATERIALS: This study was undertaken through the American Association of Physicists in Medicine's Working Group on Biological Effects of Stereotactic Body Radiotherapy. Data from studies of lung SBRT published through the summer of 2016 that provided detailed information about RILT were analyzed. RESULTS: Ninety-seven studies were ultimately considered. Definitions of the risk organ and complication endpoints as well as dose-volume information presented varied among studies. The risk of RILT, including radiation pneumonitis and pulmonary fibrosis, was reported to be associated with the size and location of the tumor. Patients with interstitial lung disease appear to be especially susceptible to severe RILT. A variety of dosimetric parameters were reported to be associated with RILT. There was no apparent threshold "tolerance dose-volume" level. However, most studies noted safe treatment with a rate of symptomatic RILT of <10% to 15% after lung SBRT with a mean lung dose (MLD) of the combined lungs ≤8 Gy in 3 to 5 fractions and the percent of total lung volume receiving more than 20 Gy (V20) <10% to 15%. CONCLUSIONS: To allow more rigorous analysis of this complication, future studies should standardize reporting by including standardized endpoint and volume definitions and providing dose-volume information for all patients, with and without RILT.
引用
- Kong FS, Moiseenko V, Zhao J, et al. Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma? Int J Radiat Oncol Biol Phys. 2018. PMID: 30496880. doi:10.1016/j.ijrobp.2018.11.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。